

“I TRIED TOPICAL RXs  
AND EXPERIENCED  
LITTLE RELIEF UNTIL  
DUPIXENT. NOW LESS  
ITCH AND CLEARER  
SKIN.”

- Jennifer

## MEET JENNIFER

Age 42

Currently taking DUPIXENT



Real patient being treated with DUPIXENT. Individual results may vary.

### MY STORY

I was treated by a pediatrician starting at age 5 and later by a dermatologist. When they both ran out of ideas for my uncontrolled moderate-to-severe atopic dermatitis, I was referred to an allergist.

### INDICATION

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

### IMPORTANT SAFETY INFORMATION

**CONTRAINDICATION:** DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

### WARNINGS AND PRECAUTIONS

**Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

### MY SIGNS AND SYMPTOMS

- Persistent itch and cracking, peeling skin that would ooze
- Lesions made it difficult for me to swim and perform musical theater in costume
- My itch felt like a constant sunburn

### MY TREATMENT AND GOALS

- Oral and topical prescription steroids were not enough to help address the itch-scratch cycle
- I also tried immunosuppressants, UVB treatment 3 times a week, and bleach baths with no success
- I wanted itch relief—lasting change was my goal

# THE DATA BEHIND THE STORY

## RAPID ITCH REDUCTION AND SUSTAINED DISEASE CONTROL DEMONSTRATED AT 52 WEEKS<sup>1,3</sup>



51%

DUPIXENT + TCS

VS

13%

PLACEBO + TCS

adult patients who achieved **≥4-point reduction in Peak Pruritus NRS** at Week 52 in CHRONOS ( $P < 0.0001$ ; secondary endpoint)

- **Rapid itch reduction seen as early as Week 2** in some patients (**≈18%** with DUPIXENT + TCS [n=102] vs **8%** with placebo + TCS [n=299]; secondary endpoint;  $P = 0.0062$ )<sup>3</sup>



65%

DUPIXENT + TCS

VS

22%

PLACEBO + TCS

adult patients who sustained **≥75% improvement in lesion extent and severity** at Week 52 in CHRONOS ( $P < 0.0001$ ; secondary endpoint)

- **39%** of DUPIXENT + TCS patients achieved **clear or almost-clear skin** (IGA 0 or 1) vs **12%** with placebo + TCS at Week 16 in CHRONOS (primary endpoint;  $P < 0.0001$ )<sup>1,2</sup>

**TRIAL DESIGNS AND RESULTS:** 917 adults in SOLO 1 and SOLO 2 (16 weeks each) and 421 adults in CHRONOS (52 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT or placebo. All patients in CHRONOS were treated with concomitant TCS. All patients who received DUPIXENT were given 300 mg Q2W after a 600 mg loading dose. Patients had an IGA score  $\geq 3$  on a scale of 0 to 4, an EASI score  $\geq 16$  on a scale of 0 to 72, and BSA involvement of  $\geq 10\%$ . At baseline, 52% had an IGA score of 3 (moderate), 48% had an IGA of 4 (severe), mean EASI score was 33, and weekly averaged Peak Pruritus NRS was 7 on a scale of 0 to 10.<sup>2</sup>

The primary endpoint was the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and  $\geq 2$ -point improvement at Week 16 (38% and 36% of patients treated with DUPIXENT vs 10% and 9% with placebo in SOLO 1 and SOLO 2, respectively,  $P < 0.001$ ; 39% of patients treated with DUPIXENT + TCS vs 12% with placebo + TCS in CHRONOS,  $P < 0.0001$ ). Other endpoints included the proportion of subjects with EASI-75 at Week 16 (51% and 44% of patients treated with DUPIXENT vs 15% and 12% with placebo in SOLO 1 and SOLO 2, respectively,  $P < 0.001$ ; 69% of patients treated with DUPIXENT + TCS vs 23% with placebo + TCS in CHRONOS,  $P < 0.0001$ ) and  $\geq 4$ -point improvement in the Peak Pruritus NRS at Week 16 (41% and 36% of patients treated with DUPIXENT vs 12% and 10% with placebo in SOLO 1 and SOLO 2, respectively,  $P < 0.001$ ; 59% of patients treated with DUPIXENT + TCS vs 20% with placebo + TCS in CHRONOS,  $P < 0.0001$ ).<sup>1,2,4</sup>

AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS (cont'd)

**Conjunctivitis and Keratitis:** Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

**Risk Associated with Abrupt Reduction of Corticosteroid Dosage:** Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

**Atopic Dermatitis Patients with Co-morbid Asthma:** Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

# VISIBLE RESULTS

## ADULT PATIENT—ACHIEVED A 3-POINT IMPROVEMENT IN IGA

This adult patient was an actual patient treated with DUPIXENT. Not a clinical trial patient. Note that this patient was on concomitant therapies, such as TCS, phototherapy, etc., at the prescribing physician's discretion. Scoring was designated by the treating physician. Because this patient was a real-world patient, other factors may have influenced treatment results, and individual results may vary.

BASELINE: IGA 3 (moderate)



WEEK 16: IGA 0 (clear)



A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline.<sup>2</sup>



THE FIRST AND ONLY BIOLOGIC APPROVED TO TREAT UNCONTROLLED MODERATE-TO-SEVERE AD FROM INFANCY TO ADULthood (6+ MONTHS OF AGE)

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS (cont'd)

**Arthralgia:** Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

**Parasitic (Helminth) Infections:** It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

**Vaccinations:** Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

**DUPIXENT**<sup>®</sup>  
(dupilumab) Injection  
200mg · 300mg

# DEMONSTRATED LONG-TERM SAFETY PROFILE

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent with the Week 16 adult safety profile<sup>2</sup>

Adverse reactions occurring in ≥1% of adult patients through Week 16<sup>2</sup>

Adverse reaction	DUPIXENT 300 mg Q2W monotherapy <sup>a</sup>		DUPIXENT 300 mg Q2W + TCS <sup>b</sup>	
	DUPIXENT <sup>c</sup> (n=529) %	Placebo (n=517) %	DUPIXENT + TCS <sup>c</sup> (n=110) %	Placebo + TCS (n=315) %
Injection site reaction	10	5	10	6
Conjunctivitis <sup>d</sup>	10	2	9	5
Blepharitis	<1	<1	5	1
Oral herpes	4	2	3	2
Keratitis <sup>e</sup>	<1	0	4	0
Eye pruritus	1	<1	2	1
Other herpes simplex virus infection <sup>f</sup>	2	1	1	<1
Dry eye	<1	0	2	<1

Treatment-emergent eosinophilia (≥5,000 cells/mcL) was reported in<sup>2</sup>:

- <3% of DUPIXENT-treated subjects and <0.5% of placebo-treated subjects (SOLO 1, SOLO 2, and AD-1021; DRI12544, QUEST, and VOYAGE; SINUS-24 and SINUS-52; PRIME and PRIME2)<sup>g</sup>
- 8% of DUPIXENT-treated subjects and 0% of placebo-treated subjects (AD-1539)

<sup>a</sup>Pooled analysis of SOLO 1, SOLO 2, and AD-1021 (phase 2 dose-ranging study). <sup>b</sup>Analysis of CHRONOS in which subjects were on background TCS therapy. <sup>c</sup>DUPIXENT 600 mg at Week 0, followed by 300 mg every 2 weeks. <sup>d</sup>Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation. <sup>e</sup>Keratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex. <sup>f</sup>Other herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex otitis externa, and herpes virus infection, but excludes eczema herpeticum. <sup>g</sup>DRI12544, QUEST, and VOYAGE are part of the asthma clinical trial program; SINUS-24 and SINUS-52 are part of the chronic rhinosinusitis with nasal polyposis clinical trial program; PRIME and PRIME2 are part of the prurigo nodularis clinical trial program.

## IMPORTANT SAFETY INFORMATION

**ADVERSE REACTIONS:** The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

# IMPORTANT CONSIDERATIONS



IN AN OPEN-LABEL EXTENSION (OLE) CLINICAL TRIAL IN ADULTS

**LONG-TERM SAFETY PROFILE THROUGH ≈5 YEARS WAS GENERALLY CONSISTENT WITH AD CONTROLLED STUDIES<sup>2</sup>**

- **AD-1225 STUDY DESCRIPTION:** The OLE safety data reflect exposure to DUPIXENT 200 mg QW, 300 mg QW, and 300 mg Q2W in 2677 subjects, who had varying lengths of treatment exposure (179 subjects exposed for at least 260 weeks). In DUPIXENT clinical trials, QW dosing did not demonstrate additional treatment benefit over Q2W dosing

## DUPIXENT ATTRIBUTES AND CONSIDERATIONS



**NOT AN IMMUNOSUPPRESSANT<sup>2</sup>**



**NO INITIAL LAB TESTING OR ONGOING LAB MONITORING**

according to the Prescribing Information<sup>2</sup>



**NO KNOWN DRUG-TO-DRUG INTERACTIONS<sup>2</sup>**

- Not metabolized through the liver or excreted through the kidneys



**NO BOXED WARNING<sup>2</sup>**

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information throughout.

QW, once weekly.

## IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

**Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.


**References:** 1. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017;389(10086):2287-2303. 2. DUPIXENT Prescribing Information. 3. Data on file, Regeneron Pharmaceuticals, Inc. 4. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335-2348.

**DUPIXENT<sup>®</sup>**  
(dupilumab) Injection  
200mg · 300mg

WHEN TOPICAL Rx THERAPIES ARE NOT ENOUGH, DUPIXENT:

# YOUR FIRST CHOICE

TO ADEQUATELY CONTROL THIS CHRONIC, SYSTEMIC DISEASE



Real patient  
being treated  
with DUPIXENT.  
Individual results  
may vary.



### In some adults treated with DUPIXENT + TCS

- Rapid itch reduction after the first dose (as measured at Week 2); Week 16 results sustained at 1 year<sup>1,3</sup>
- ≥75% improvement in lesion extent and severity (EASI-75) at Week 16 sustained at 1 year<sup>1,2</sup>
- Clear or almost-clear skin (IGA 0 or 1) at Week 16<sup>1,2</sup>



**NOT AN IMMUNOSUPPRESSANT<sup>2</sup>**



**NO REQUIREMENT FOR INITIAL LAB TESTING OR ONGOING LAB MONITORING,** according to the Prescribing Information<sup>2</sup>



**NO BOXED WARNING<sup>2</sup>**

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information throughout.

**52**  
WEEKS

### A demonstrated long-term safety profile in adult patients<sup>2</sup>

- **Most common adverse reactions (incidence ≥1%) are** injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia
- The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent with the Week 16 adult safety profile

**#1** prescribed biologic  
by dermatologists<sup>3,a</sup>

**6 YEARS**  
since initial FDA approval in AD<sup>2,b</sup>

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS

**Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

<sup>a</sup> IQVIA NBRx data as of JUNE 2023.

<sup>b</sup> FDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe atopic dermatitis.



SEE HOW OTHER PATIENTS LIKE  
JENNIFER ACHIEVE CHANGE IN ITCH  
AND SKIN LESIONS WITH DUPIXENT

sanofi

REGENERON<sup>®</sup>